Disease Overview：Chronic Inflammatory Demyelinating Polyneuropathy（CIDP）
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired, immune-mediated disorder characterized by progressive or relapsing symmetric weakness and sensory dysfunction in the limbs, resulting from demyelination of peripheral nerves. Diagnosis relies on clinical evaluation, electrophysiological studies (e.g., slowed nerve conduction velocities, prolonged distal latencies), cerebrospinal fluid analysis showing elevated protein without pleocytosis, and supportive MRI or nerve biopsy findings. First-line therapies include intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange; refractory cases may require rituximab or other immunomodulatory agents. Early intervention significantly improves functional recovery and reduces long-term disability.
China offers distinct advantages for CIDP management: leading neurology centers—such as Beijing Union Medical College Hospital and Shanghai Huashan Hospital—host internationally trained specialists with extensive experience in rare neuropathies and access to advanced diagnostic tools, including high-resolution nerve ultrasound, quantitative sensory testing, and next-generation sequencing for differential diagnosis. Clinical outcomes align with global benchmarks, with published cohort studies reporting ≥70% sustained response rates to IVIG or combination regimens. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality or regulatory oversight—China’s NMPA-approved biologics and domestically manufactured IVIG meet stringent WHO-GMP standards. As a dedicated medical tourism agency, we facilitate seamless international care: verifying physician credentials, coordinating appointments at accredited hospitals, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.
Chronic Inflammatory Demyelinating Polyneuropathy: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Non-Surgical / Conservative / Medication Options
*Target Criteria:* Confirmed CIDP diagnosis (EFNS/PNS criteria), ≥2 months symptom duration, progressive or relapsing course, electrophysiological/CSF evidence of demyelination.
- •First-Line Immunomodulation
- *Corticosteroids (Prednisone taper)*: ¥120–¥280 ($17–$39) monthly (drug only); monitoring labs (CBC, LFTs, glucose) add ¥420 ($58) per quarter. - *Plasma Exchange (PLEX)*: ¥3,200–¥4,100 ($445–$570) per session; 5–7 sessions over 2 weeks (total ¥16,000–¥28,700 / $2,220–$3,990).
- •Diagnostic & Monitoring Fees (Per Episode)
- Lumbar Puncture + CSF analysis: ¥860 ($120) - Serum IgG/IgM/IgA + autoantibody panel (e.g., NF155, CNTN1): ¥1,980 ($275) - MRI lumbosacral plexus (if indicated): ¥1,200 ($167)
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Refractory CIDP (failure of ≥2 first-line therapies), severe disability (MRC sum score <40), or life-threatening respiratory involvement.
- •Autologous Hematopoietic Stem Cell Transplantation (AHSCT)
- Mobilization + collection + conditioning + transplant + 30-day inpatient care: ¥248,000–¥312,000 ($34,400–$43,300) - *Note:* Only offered at designated centers (e.g., PUMCH, Ruijin Hospital); requires multidisciplinary neurology-hematology approval.
Special / Complex Condition Options
- •Refractory CIDP with Anti-NF155 Antibodies: Rituximab (375 mg/m² × 4 weekly doses): ¥42,600–¥51,200 ($5,920–$7,110) total (drug + infusion + monitoring).
- •CIDP with Severe Respiratory Failure Requiring Ventilation Support: ICU admission (per day): ¥4,800–¥6,200 ($667–$861); mechanical ventilation setup: ¥3,500 ($486).
Quick Selection Guide
- •<50 years, no comorbidities, moderate severity: Start with IVIG (optimal efficacy/safety ratio); budget $2,200–$3,000 for induction.
- •≥65 years, diabetes/hypertension, mild-moderate disease: Prednisone + close monitoring; total 6-month cost <$500 (drug + quarterly labs).
- •Young adult, rapid progression, anti-CNTN1+: Prioritize PLEX for acute stabilization ($2,200–$4,000), then transition to rituximab.
- •Refractory, wheelchair-dependent, failed 3 therapies: AHSCT evaluation—only if ECOG ≤2 and organ function preserved; reserve for centers with ≥5-year CIDP transplant experience.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Chronic Inflammatory Demyelinating Polyneuropathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Chronic Inflammatory Demyelinating Polyneuropathy treatment with China top medical destinations:
